Discover what FDA's red dye ban means for your food safety. Learn which synthetic colors remain in your favorite foods and their potential health risks.

The U.S. Food and Drug Administration wants to put nutrition information front and center on food products to give consumers an easier way to identify nutrients linked to chronic diseases. The FDA announced its plans to push for a rule that would require food manufacturers to include a front-of-package nutrition label on most packaged food products.

An injectable blood pressure drug has been recalled after the FDA has warned it could cause side effects, such as stroke or death.

Over 35 years after the first study linking the artificial food dye Red 3 to thyroid cancer in rats was published, the U.S. is beginning to phase it out of foods and drugs.

President Donald Trump's first week in office came with big changes to U.S. health agencies, including the pausing of all external communications and banning travel.

In 2024, food recalls in the US seemed to soar. Between headline-making outbreaks of listeria and E. coli and problems with undeclared allergens and other possible contaminants, there were 1,908 food and cosmetic recalls during the US Food and Drug Administration's 2024 fiscal year, which ran from Oct. 1, 2023, to Sept. 30, 2024.

Red No. 3, also known as erythrosine, is a color additive made from petroleum that gives foods and drinks a bright, cherry-red color.

The FDA announced the changes in a “ prevention strategy ” to keep fresh and frozen berries from being contaminated with enteric viruses. Enteric viruses are viruses that can infect the intestines, causing symptoms like nausea, diarrhea, and stomach pain. These include illnesses like norovirus and hepatitis A.

Research shows toxic additives have been overlooked in the U.S. food supply, though the federal Food and Drug Administration is charged with regulating them. Legislation in Montana could start new state-level rules.

The Kirkland Signature brand smoked salmon was distributed to locations including Costo Warehouse stores in Florida.

Sage Therapeutics said on Monday that its board has unanimously rejected Biogen’s $469 million offer, stating it "significantly undervalues" the company and does not serve shareholders' best interests.